Therapeutics Supplements and Botanicals

The Effect of Berberine on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Control Trials

Xie L, Zhang D, Ma H, He H, Xia Q, Shen W, Chang H, Deng Y, Wu Q, Cong J, Wang CC, Wu X

Published December 13, 2019 Evidence-based Complementary and Alternative Medicine : eCAM, 2019, 7918631
DOI 10.1155/2019/7918631 PMID 31915452 PMC PMC6930782

RRM Academy Synopsis

Berberine showed no solid live birth benefit in PCOS trials

This review pooled 12 randomized trials in 1,544 women with PCOS, also now called PMOS (polyendocrine metabolic ovarian syndrome). Live birth with berberine was similar to metformin and lower than letrozole, each from one trial. Berberine was linked to lower testosterone and cholesterol in some comparisons.

Key Findings

  • Live birth against letrozole, one trial: risk ratio 0.61 (95% CI 0.44 to 0.82), lower with berberine. Against metformin, one trial: 1.32 (95% CI 0.78 to 2.25), similar.
  • Live birth against placebo, both with letrozole, one trial: risk ratio 0.95 (95% CI 0.73 to 1.23). Pregnancy against placebo or no treatment, 4 trials: 1.46 (95% CI 0.90 to 2.36).
  • Against metformin, total cholesterol was lower (3 trials, 201 participants; mean difference -0.44, 95% CI -0.60 to -0.29), as was waist-to-hip ratio (4 trials; -0.04, 95% CI -0.05 to -0.03).
  • Against metformin, body mass index showed no clear difference (4 trials, 262 participants; mean difference -0.03, 95% CI -0.46 to 0.39).
  • Stomach side effects against placebo were similar (3 trials, 567 participants; risk ratio 1.01, 95% CI 0.76 to 1.35), as were serious events in pregnancy (0.98, 95% CI 0.70 to 1.37).

Interpretation

This review pooled randomized trials comparing berberine with metformin, letrozole, placebo, or no treatment in women with PCOS. Live birth with berberine was similar to metformin and lower than letrozole, each from a single trial. Cholesterol and waist-to-hip ratio were lower with berberine than metformin. The authors note that all the trials enrolled women in mainland China. The findings support larger studies of this approach.

RRM Context

Restorative reproductive medicine treats PMOS as a hormone and metabolic condition. It looks for causes, like insulin resistance, before treatment starts. The cholesterol and waist-to-hip findings here are metabolic markers. Live birth matters most to couples. Berberine matched metformin but was lower than letrozole in single trials.

Abstract

Purpose

To assess the efficacy and safety of berberine on reproductive endocrine and metabolic outcomes in women with polycystic ovary syndrome (PCOS).

Methods

PubMed (from 1950), the Cochrane Library, the CNKI (from 1979), the VIP (from 1989), and the Wanfang Data (from 1990) and the reference lists of the retrieved articles were searched for randomized controlled trials in human beings with the search terms including "polycystic ovary syndrome/PCOS" and "berberine/BBR/Huangliansu (in Chinese)/Xiao bojian (in Chinese)" till 30 May 2019. Relevant indicators were collected and the data were analyzed by using RevMan 5.3 software.

Results

Eventually, a total of 12 randomized controlled trials were included in this systematic review. Our study suggested that berberine had similar live birth rates compared with placebo or metformin and lower live birth rates (RR: 0.61, 95% CI: 0.44 to 0.82) compared with letrozole. There was a significant difference between berberine and placebo and between berberine and no treatment in terms of decreasing total testosterone and luteinizing hormone to follicle-stimulating hormone (LH/FSH) ratio (8 RCTs, 577 participants, MD: -0.34, 95% CI: -0.47 to -0.20; 3 RCTs, 179 participants, MD: -0.44, 95% CI: -0.68 to -0.21, respectively). Berberine was associated with decreasing total cholesterol (3 RCTs, 201 participants; MD: -0.44, 95% CI: -0.60 to -0.29), waist circumference (3 RCTs, 197 participants, MD: -2.74, 95% CI: -4.55 to -0.93), and waist-to-hip ratio (4 RCTs, 258 participants, MD: -0.04, 95% CI: -0.05 to -0.03) compared with metformin, but not with improved BMI (4 RCTs, 262 participants, MD: -0.03, 95% CI: -0.46 to 0.39). Berberine did not increase the incidence of gastrointestinal adverse events (3 RCTs, 567 participants, RR: 1.01, 95% CI: 0.76 to 1.35) or serious events during pregnancy (RR: 0.98, 95% CI: 0.70 to 1.37) compared with placebo.

Conclusion

This review found no solid evidence that berberine could improve live birth or other clinical outcomes in women with PCOS. However, berberine appeared to be more efficacious for improving insulin resistance and dyslipidemia and decreasing androgen levels and LH/FSH ratio in women with PCOS when compared with metformin.

Topics

Related research

Therapeutics › Supplements and Botanicals › Herbal and Botanical Products · Reproductive Endocrinology › Ovarian Hormones › Androgens · Infertility › Ovulation Induction › Letrozole
Liangzhen Xie, Duojia Zhang, Hongli Ma, Hui He, Qing Xia, Wenjuan Shen, Hui Chang, Yingying Deng, Qi Wu, Jing Cong, Chi Chiu Wang, Xiaoke Wu
L Xie, D Zhang, H Ma, H He, Q Xia, W Shen, H Chang, Y Deng, Q Wu, J Cong, C Wang, X Wu
PMID 31915452 31915452 DOI 10.1155/2019/7918631 10.1155/2019/7918631 Xie et al. 2019, Xie 2019